Vor Biopharma Inc

Vor Biopharma Inc. a clinical-stage company engages in the development of engineered hematopoietic stem cell (eHSC) therapies for cancer patients. The company is developing lead product tremtelectogene empogeditemcel (trem-cel) formerly VOR33 an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. It also offers Mylotarg a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33 a CAR-T therapy designed to target CD33 a clinically validated target for AML currently under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system currently under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T currently under preclinical studies for the treatment of AML. Vor Biopharma Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge Massachusetts.